Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Clinical trial NCT04566133 · TERMINATED
Trial details
- NCT number
- NCT04566133
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-15
- Primary completion
- 2022-05-11
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.